As the death of actor Chadwick Boseman recently made clear, the prognosis for those with metastatic colorectal cancer is poor. Diet and lifestyle factors such as how much red meat you eat, smoking, drinking alcohol to excess and being sedentary can all reduce a person’s chances of survival and increase the risk that the disease will progress.
The good news is that drinking coffee appears to improve these outcomes.
Coffee has been found to prevent the formation of neoplasms, abnormal masses of tissue that may become cancerous, in the lab. Studies of patients with stage 3 colon cancer have also reported that greater coffee consumption is associated with improved survival.
Coffee, researchers showed, reduces the risk of recurrence of colorectal cancer. Now a study of has found that drinking coffee slowed the progression of the disease among colorectal cancer patients and improved their overall survival.
Almost 1,200 people across the U.S. who had advanced or metastatic colorectal cancer that had not been previously treated participated in a clinical trial comparing therapies. The median age of participants was 59 years old. The patients were followed, on average, for a little more than five years.
Both caffeinated and decaffeinated coffee offered the same benefits.
The patients reported the number of decaffeinated and caffeinated cups of coffee they typically drank each day when they enrolled in the clinical trial. Those who drank two to three cups of coffee per day lived longer and were less likely to have the disease progress compared to those who did not drink coffee. Those who drank four or more cups of coffee per day had an even better survival rate and lower risk of disease progression. Both caffeinated and decaffeinated coffee offered the same benefits.
The study did not provide researchers with information allowing them to pinpoint why drinking coffee is beneficial, or which compounds in coffee were responsible for the anti-inflammatory and antioxidant properties that make it effective against cancer, Mackintosh, a medical student at the Alix School of Medicine at the Mayo Clinic in Phoenix, explained.